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Increasing amounts of tau protein were expressed in non-neuronal cells. When intracellular
amounts reached a threshold level, tau protein was released to the extracellular culture medium
in association with membrane vesicles. Hence, we propose that taumight be secreted throughmem-
brane vesicles as a cellular mechanism to eliminate the excess of tau protein, thereby avoiding its
toxicity.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recent reports suggest that high levels of tau protein might beIntracellular levels of a protein are usually the result of the bal-
ance between its synthesis and degradation. Protein degradation
takes place by two main mechanisms: through the proteasome
system or by the autophagy-lysosome system. In the case of tau
protein, degradation through both systems, proteasome [1,2] and
autophagy-lysosome [3], has been suggested. In addition, protein
secretion through microvesicles (MVs) has been proposed to be
an alternative pathway to decrease intracellular levels of certain
proteins in order to facilitate protein discharge, cell differentiation
or intercellular communication [4,5].
At least two types of MVs, based on their intracellular origin,
have been described: exosomes, originated by inward budding of
the multivesicular bodies (late endocytic compartments) and
microparticles, which are originated by outward budding from
the plasma membrane [4–7]. MVs are released by most cell-types
[4], including microglia [8] or neurons [9,10] and have been pro-
posed to play a role in the development of neurological diseases,
such as Alzheimer [11] or prion disease [12].chemical Societies. Published by E
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javila@cbm.uam.es (J. Avila).toxic for cells [13]. This protein could interact with plasma mem-
branes [14], and this interaction is mediated by tau amino-termi-
nal projection domain [14–16] and regulated by phosphorylation
[17]. In this regard, vesicle packaging of proteins may be facilitated
by the interaction of the protein with cell membranes. Recently, a
hypothesis suggesting the secretion of intracellular tau through
membrane vesicles has been proposed [18,19].
However, it has been shown that under normal conditions tau
protein is not detected in exosome-like vesicles secreted to the
extracellular space from primary cultured cortical neurons [9].
In this work, we have expressed tau protein in two non-tau-
expressing kidney-derived cell-lines, at different levels, and tested
if above a certain intracellular protein amount, tau protein could be
detected in the conditioned medium of tau-overexpressing cells.
Our results indicate that, indeed, an excess of intracellular tau
leads to its secretion outside the cell in association with MVs,
supporting that this could be a mechanism involved in the homeo-
stasis of this protein.2. Materials and methods
2.1. Materials
The antibody 7.51which recognizes total tauwas kindly donated
by Dr. Wischik (Medical Research Council Center, Cambridge, UK)lsevier B.V. All rights reserved.
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Biologicals (Cambridge, UK). LAMP2 antibody was obtained from
Santa Cruz Biotechnology. Antibodies against LAMP1 and CD63
protein were purchased to Developmental Studies Hybridoma Bank
(Iowa City, USA) and CD81 was from BD Biosciences (Mountain
View, USA). Rabbit polyclonal antibody against LIMP-2 was pur-
chased to Abcam (Cambridge, UK). Antibodies against b-actin and
b-tubulin were obtained from Sigma. The anti-proteases cocktail
was obtained from Sigma–Aldrich.
2.2. Cell culture and DNAs transfection
Human embryonic kidney (HEK-293) and tau-stably expressing
HEK-293 (HEK-Tau) cells were cultured as previously described
[21]. African green monkey kidney ﬁbroblasts (COS-7) cells [22]
were grown in Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% (vol/vol) FBS. Cells were transfected with pSGT42 cDNA
(pSGTau) [23] using lipofectamine 2000 reagent (Invitrogen).
Control cells were transfected with the empty vector pSG5. At dif-
ferent times after transfection the cells were collected for Western
blotting or were ﬁxed for immunoﬂuorescence analysis.
2.3. Primary cultures of cortical neurons
Cells were obtained from cortex of C57BL/6 mouse embryos at
day 18 (E18) as described with modiﬁcations [24]. Cells were dis-
sociated with the Papain Dissociation System (PDS; Worthington
Biochemical Corporation, Lakewood, NJ, USA). Neurons were
seeded on and maintained in Neurobasal medium supplemented
with B-27 (Gibco, Grand Island, NY, USA), 0.5 mM glutamine and
antibiotics, and grown on poly-l-lysine (100 mg/ml) coated plastic
dishes or glass coverslips. The cells were incubated in a humidiﬁed
incubator at 37 C and 5% CO2.
2.4. Isolation of membrane vesicles
The culture media of the different cell types were collected after
48 h, except in the indicated case that were collected after 1 week.
The isolation of microvesicles was done as described in Théry et al.
[25] by differential centrifugation of the conditioned medium
(300g for 10 min; 2000g 10 min; 10000g 30 min) at 4 C to re-
move cell debris followed by one at 100.000g for 90 min at 4 C to
pellet the vesicles. Vesicles were washed with phosphate-buffered
saline (PBS), followed by another ultracentrifugation at 100.000g
for 90 min. After this procedure, microvesicles were resuspended
in protein-loading buffer for Western blot analysis or in Tris-buf-
fered saline for electron microscopy visualization, using a Phillips
EM 300 electron microscopy. Immunogold labelling microscopy
was carried out as previously described [25]. Protein A-gold
(PAG) or goat anti-mouse-gold antibody was used to detect Tau
and CD63 antibodies, respectively.
2.5. Toxicity assays
Cell death was assayed by using the LIVE/DEAD viability/cyto-
toxicity kit (Invitrogen, Carlsbad, CA), that contains calcein AM, that
only labels live cells, and ethidium homodimer-1, that enters cells
with loss of plasma membrane integrity (dead cells). After staining,
live cells (calcein-labelled, green) and dead cells (ethidiumhomodi-
mer-1-labelled, red) were visualized on a Leica ﬂuorescence micro-
scope and images were taken. Cell death was deﬁned in each
condition as the percentage of dead cells versus the total number
of cells.
For the assays performed to analyze the toxicity ofmicrovesicles,
the amount of vesicles isolated from about 4  107 of HEK293 or
HEK-Tau cells, were added to each well of a 24-well plate in whichthe cortical neurons were seeded at a density of 1–2  105 cells
perwell. After 4DIV theneuronal viabilitywasmeasuredusing LIVE/
DEAD viability kit.
2.6. Iodixanol continuous density gradient
Optiprep iodixanol density media was obtained from Sigma–Al-
drich. Continuous density gradients were performed as described
in Augustin et al., 2005 [26] with some adaptations. Brieﬂy,
5  106 cells were washed three times in PBS and resuspended in
200 ll 0.25 M sucrose, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM EGTA,
50 mM Hepes-NaOH at pH 7.0 with Complete mixture of Protease
Inhibitor (Sigma). Cells were lysed by 35 strokes of a Dounce
homogenizer and centrifuged at 1000 g for 5 min twice to remove
cellular debris and nuclei. Continuous 5–30% iodixanol gradients
were prepared in 78 mM KCl, 4 mM MgCl2, 8.4 mM CaCl2,
10 mM EGTA and 50 mM Hepes-NaOH at pH 7.0 using a gradient
mixer. Post-nuclear supernatant was added to the top of 13 ml gra-
dients and centrifuged at 90000 g for 20 h using a SW32 swinging
bucket Beckman rotor. Fractions of 1 ml were collected from the
top of the gradient using an auto densi-ﬂow density gradient frac-
tionator (Labconco Corp., Kansas City, MO). Fraction densities were
calculated from refractive index measured using a refractometer.
For analysis, proteins were precipitated by addition of a ﬁnal con-
centration of 20% trichloroacetic acid (4 C, 30 min), washed with
acetone and ethanol, and resuspended in 1/5th of the initial lysis
buffer volume of 100 mM Tris–HCl at pH 8.8 with loading solution.
20 ll of the fractions were analyzed by Western-blotting using
antibodies against different intracellular markers.
2.7. Western immunoblotting
Denaturing gel electrophoresis was performed in 10% or gradi-
ent 4–12% SDS–PAGE gels in Tris-glycine buffer. After the electro-
phoresis, the fractioned proteins were blotted into nitrocellulose
membranes, the total transferred proteins were determined by
Ponceau’s staining and afterwards were incubated with different
antibodies to identiﬁed some of the fractionated proteins.
2.8. Immunocytochemistry
For confocal microscopy, cells were grown on glass coverslips,
ﬁxed with 4% paraformaldehyde for 15 min and washed by phos-
phate suffered saline (PBS). After PBS washes, cells were blocked
with 1% FBS/0.1% Triton X-100-PBS and the coverslips were
washed again. Primary antibodies were added to the washed cov-
erslips and incubated for 2 h at room temperature. Then, the cov-
erslips were washed with PBS and incubated with the secondary
antibody. After washing with PBS, the coverslips were mounted
with Fluorosave™ (Calbiochem, San Diego, CA).
3. Results
3.1. Overexpression of tau in COS-7 cells results in tau release to the
extracellular space
Tau protein is an intracellular protein that is mainly present at
the cell cytoplasm [27]. Indeed, in mouse cortical neurons cultures,
tau was not detected in the extracellular medium [9]. In this work,
we hypothesized that expression of tau protein under certain
levels does not result in its release to the extracellular space. How-
ever, tau overexpression, above threshold levels, leads to its secre-
tion. To verify that hypothesis, we expressed different amounts of
tau protein in non-neuronal cells. For that, we performed transient
transfection assays, using increasing amounts of tau constructs
Fig. 1. (A) COS-7 cells were transfected with increasing amounts of the pSG5-Tau vector (0.2, 0.4 or 2 lg), that express tau, or with the empty vector pSG5 (2 lg). The
expression of tau was analyzed by Western blotting using a monoclonal antibody against total tau. Antibody against b-actin was used as loading protein control. (B) Amount
of tau increased along the time after transfection (48 and 64 h). (C) Microtubule network of COS-7, detected by a b-tubulin antibody, was affected by the expression of high
levels of Tau, (48 and 64 h after pSG5-Tau transfection). (D) Culture media from pSG5-transfected COS-7 and from pSG5-Tau-transfected COS7 were collected and analyzed
for the presence of tau by Western blotting. (E) Quantiﬁcation by Western blotting densitometry of the levels of tau in the COS-7 transfected with increasing amounts of
pSG5-T42 (0.2–2 lg) in cell lysates (triangles) and in their respective collected medium (squares). For cell lysates, densitometry values are normalized against b-actin and in
the case of extracellular medium, serum albumin, observed by Ponceau’s staining was used as loading protein control. (F) The presence of tau in the cell lysate and in the
collected culture medium from tau-expressing HEK-293 cells (HEK-Tau) cells was also determined by Western blotting.
D. Simón et al. / FEBS Letters 586 (2012) 47–54 49(pSGTau), for different times. In these experiments, the transfec-
tion efﬁciency ranged between 60% and 80%, depending on the
different conditions used. Fig. 1A conﬁrms that intracellular
expression of tau protein increased with the amount of transfected
tau. Fig. 1B indicates that the increase in tau expression correlated
with the time after transfection, at which we lysed tau-expressing
cells. This increase in intracellular tau levels modiﬁes the microtu-
bule network organization, as shown in Fig. 1C. In that ﬁgure,
formation of tau bundles near the cell membrane was found.
To check for the presence of extracellular tau, aliquots of the
culture medium from either untransfected or transfected COS-7
cells (expressing different amounts of tau protein) were resolved
by SDS–PAGE electrophoresis, blotted into nitrocellulose mem-
branes and tested with a anti-tau antibody (Fig. 1D). Fig. 1E shows
the quantiﬁcation of the data from Fig. 1B and D. Our results
indicate that when tau was expressed at low levels, no tau could
be detected in the culture medium. However, when tau was over-
expressed in cells, a release of the protein to the extracellular
medium was observed.Additionally, we have found that in tau-stably-transfected HEK-
293 cells (HEK-Tau), a release of tau to the extracellular space was
also found (Fig. 1F).
3.2. Tau release to the extracellular medium is not related to cell death
To test whether the presence of extracellular tau was the conse-
quence of cell death, the proportion of living and dead cellswas ana-
lyzedusing a speciﬁc viability kit (see Section 2). Fig. 2 indicates that
the presence of extracellular tau did not correlated with cell death,
given the low rate of cell death observed in the cultures of transfec-
ted COS-7 cells, similar to that of both untransfected cells or cells
transfected with an empty vector (see quantiﬁcation in Fig. 2B).
3.3. Tau protein is secreted to the extracellular space in association
with MVs
As already mentioned, MVs could be originated from endocytic
compartments. In addition, tau has been reported to be associated
Fig. 2. (A) Cell viability of COS-7 cells under control conditions (c), transfected with empty pSG5 or with pSG5-Tau vector, was measured by viability/cytotoxicity assay by
labelling with calcein-AM (live cells) and ethidium homodimer-1 (dead cells), 96 h after transfection. (B) Quantiﬁcation of the percentage of dead cells in each condition is
shown.
Fig. 3. (A) Confocal micrographs of tau-stably expressed HEK-293 (HEK-Tau) cells immunostained using LAMP1 (late endosomal/lysosomal marker) and tau antibodies. (B)
Density fractionation of post-nuclear supernant from tau-expressing cells (Hek-Tau). Nine fractions of a 5–30% iodixanol gradient with the indicated densities was analyzed
by Western blotting against tau protein and different markers including cytosolic (Hsp70, b-actin), endoplasmic reticulum (GRP78), late endosomes and lysosomes integral
membrane (LIMP-2) and non-integral membrane and multivesicular bodies (TSG101), and ‘‘lipid rafts’’ (Flotillin).
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immunocytochemical analyses, we showed a partial colocalization
of tau with LAMP1, a marker for late endosomes and lysosomes
(Fig. 3A). This suggested the possible localization of tau in late
endocytic compartments.In order to corroborate this ﬁnding, a gradient fractionation ap-
proach was performed, and the distribution of tau along the differ-
ent fractions was evaluated by Western blot. In Fig. 3B, tau was not
detected in late endosome fractions, deﬁned by the presence of the
LIMP-2 marker. However, a certain amount of tau co-fractionated
Fig. 4. (A) The presence of Tau was analysed in either cells lysates (pellet), culture medium (supernatant) or extracellular vesicles isolated from the culture media of
transfected COS-7 cells with empty pSG5 or with pSG5-Tau vector. (B) The culture media of HEK-293 (HEK) or Tau-stably expressed HEK-293 (HEK-Tau) cells were collected
and membrane vesicles were isolated from them. Western blot analysis, using a 10% acrylamide gel, shows the presence of detectable amounts of tau in the culture medium
and in vesicles fraction in HEK-Tau. An antibody against LAMP2 protein was used as a marker of microvesicles. Antibody against b-tubulin was used as a control to show that
no cells were contaminating the vesicle fraction. (C) The cell lysates of HEK-Tau cells and the vesicles isolated from their culture media after 1 week of culturing were resolved
on a 4–12% acrylamide gel (to see the smallest tau fragments) and analyzed by Western blotting using an antibody against total tau and CD81 (exosomal marker). (D) A
cocktail of proteases inhibitors were added (IP) or not (C) to the culture medium of HEK-Tau during 48 h and the microvesicles were isolated from it. These were examined for
the presence of tau by Western blot. The arrowhead indicates non-cleaved tau.
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hsp70, b-actin and GRP78, which have been found in exosomes by
proteomics studies [4,30]. These result are compatible with a
possible secretion of tau to the extracellular medium in association
with these kind of MVs, in agreement with other reports that
previously hypothesized that tau protein could be released to the
extracellular medium through vesicles [18,19]. To test if this is
the case, we overexpressed tau in cultured COS-7 cells and the
extracellular medium of that culture was centrifuged, as described
in Section 2, to purify and characterize MVs released by transfected
cells. Fig. 4A reveals the presence of tau protein in the vesicular
fractions from tau-transfected COS-7 cells and, as shown in
Fig. 4B, tau was found both, in the supernatant and vesicular frac-
tions from tau-stably-transfected HEK-293 (HEK-Tau) cells.
Interestingly, in HEK-Tau cells, vesicle-associated tau proteins
appeared to be present in degraded forms, since peptides smaller
than the full-length tau molecule were observed, specially in the
vesicle fraction obtained from media after culturing cells for
1 week (Fig. 4C). A 17 kDa tau peptide was the most abundant of
the tau-degraded forms found (see Fig. 4C). This peptide reacts
with the anti-tau antibody 7.51. this indicates that the peptide
contains residues from 315 to 376, the tau region recognized by
the antibody [20]. Tau degradation could be due to the action of
proteases released to the extracellular medium or present in the
MVs derived from endosomal–lysosomal system [3]. Indeed, when
we added a anti-proteases cocktail to the cell culture medium ofHEK-Tau during 48 h (IP) and we then puriﬁed the vesicles from
it, some non-proteolyzed tau (arrowhead) was detected in the
MVs, whereas this form of tau did not appear in the vesicles
obtained from non-treated cells (C) (Fig. 4D).
3.4. Association of tau protein with MVs
By electron microscopy analysis, the presence of 40–200 nm
(diameter) vesicles was observed in culture medium from tau-
expressing cells (HEK-tau) (Fig. 5). These structures could be
labelled with an antibody against an exosomal marker, CD63,
(Fig. 5B) and also with an anti-tau antibody (Fig. 5C and D). In addi-
tion, colocalization of this membrane vesicle marker and tau
protein was observed in some MVs (Fig. 5C and D).
3.5. Tau secreted in vesicles does not induce cell death
Extracellular vesicles from HEK-293 and HEK-Tau cells were
isolated and added to cortical neurons cultures. After vesicle addi-
tion, cell death was tested by using a kit measuring the amount of
living and dead cells (see Section 2.1). Although a slight increase in
cell death, upon the addition of HEK-Tau MVs, was observed, no
signiﬁcant differences were found between control and treated
neurons (Fig. 6A and B). Tau content in the isolated MVs was
previously analyzed by Western blot before their addition to the
neuronal cultures (Fig. 6C).
Fig. 5. Electron micrographs of extracellular membrane vesicles isolated from Tau-expressing cells (HEK-Tau) were negatively stained with 2% uranyl acetate (A, B, C, D) and
gold-immunostained with an antibody speciﬁc for CD63 (exosomal marker) in B (10 nm gold) and together with a polyclonal antibody against Tau (C, D; 10 nm gold for Tau
and 5 nm gold for CD63).
Fig. 6. (A) Puriﬁed microvesicles from HEK-293 (HEK) or from tau-transfected HEK-293 (HEK-Tau) conditioned media or vehicle (DMEM medium, C) were added to primary
cortical neurons cultures and, after 4 days, viability was observed using Live/Dead Kit assay. (B) Quantiﬁcation of the percentage of dead cells in each condition is shown. (C)
Detectable amounts of tau by Western blot were found in the vesicles added to the cortical neurons culture.
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Themain conclusionof thepresentwork is that anexcessof intra-
cellular tau could be corrected by its release to the extracellular
space, through vesicles with an average diameter of 40–200 nm [7].Different types of MVs are present at the extracellular space [5],
such as microparticles that are formed by budding of the plasma
membrane, and exosomes, that are small vesicles of endocytic ori-
gin that are released by most cells [4,18], including neurons [9].
Vesicle packaging and release of cytosolic proteins could modulate
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might provide a cellular mechanism to prevent a toxic increase
in its intracellular levels. This could be an alternative mechanism,
different to the ones suggested to be principally involved in tau
clearance, proteasome [1,2] and autophagy-lysosome. For the lat-
ter, different groups have provided strong evidence that impair-
ment of this system could lead to an accumulation and
aggregation of tau [3,32]. Our data suggest that the release of tau
in association with MVs to the extracellular space, might also con-
tribute to eliminate the excess of intracellular tau (as described for
other unnecessary proteins)[33–35].
In this study, our results obtained in the gradient fractionation
assays, in which tau co-eluted with TSG101 (multivesicular bodies
marker), indicate that tau might be incorporated, by engulfment of
the surrounding cytosol, into the lumen of multivesicular bodies
during their biogenesis, in which tau could somehow associate
with the forming exosomes. This way of trapping has given expla-
nation for the incorporation to these MVs of numerous cytosolic
proteins such as hsp70, GRP78 and b-actin [4,30]. Actually, these
proteins were found in the same fractions as tau.
However, it remains to be elucidated how the excess of tau pro-
tein could get associated with this type of MVs. Although many dif-
ferent pathways have been described for the biogenesis of MVs, the
mechanisms by which proteins, are sorted to these MVs, have nei-
ther been clariﬁed yet [4]. Although, the ESCRT (endosomal sorting
complex required for transport) machinery, which includes the
TSG101 protein, was considered the best candidate to play a role
in this process [36], it has recently been reported that an alterna-
tive pathway, independent of the ESCRT, that involves ceramide,
may be implicated in the sorting of the cargo into exosomes [37].
Another idea regarding how tau could be associated with MVs
could emerge by taking into account the possible similarities be-
tween tau and a-synuclein. a-synuclein binds to vesicles through
an amphipathic alpha-helix [38]. Of note tau secondary structure
shows an amphipathic alpha-helix, which corresponds to the third
repeat in the microtubule-binding domain [39]. Moreover, it is well
known that this type of alpha-helix could be a membrane-binding
motif found in many proteins. This amphipathic behavior contrib-
utes to membrane adsorption [40], and it could be favoring the
interaction of tau with the membrane of these MVs. However, fur-
ther research would be required to address these questions.
Following their release, vesicles could be endocytosed by neigh-
boring cells. This mechanism has been proposed to explain the
propagation of missfolded or aggregated proteins in different neu-
rodegenerative disorders, including tauopathies [18,19,41]. On the
other hand, tau secretion through vesicles may be a protective
mechanism for cells overexpressing tau. Furthermore, tau secre-
tion could provide an alternative way for buffering high levels of
intracellular tau, in addition to the recently suggested one based
on the formation of tau aggregates [42]. However, whether tau
aggregation constitutes a protective mechanism remains under
discussion [42,43].
Although in normal conditions, tau does not appear to be re-
leased in exosomes from primary cultured cortical neurons [9],
data obtained from additional experiments overexpressing tau in
neurons will be relevant to know whether tau expression over a
threshold level is required for its secretion in association with
MVs in these cells.
Taken together, our present work and other previous results
[44,45], suggest that intracellular tau may be released to the extra-
cellular space, at least, in two different ways. One way would in-
volve cell death with the concomitant increase of extracellular
tau. This extracellular tau will show a toxic action, on surrounding
cells, after interacting with speciﬁc cell receptors [46,47]. This toxic
action of tau may in turn result in cell death and in the subsequent
appearance of tau in the cerebrospinal ﬂuid, in disorders such asAlzheimer disease. A second way to release tau to the extracellular
space would be its secretion via membrane vesicles. Our prelimin-
ary results indicate that tau-vesicles do not induce a signiﬁcant cell
death. However, we cannot rule out that these vesicles may have a
toxic function, since they contain a 17 KDa peptide, product of tau
degradation, that could be toxic, given that a tau peptide, with a
similar size, is toxic for different cells [48,49]. However, the 17
KDa peptide should be different to that previously reported since
it reacts with the 7.51 antibody, which recognizes residues forward
than aminoacid number 315. However, the reported peptide com-
prises residues from 45 to 230 [49]. It is likely that the found
17KDa peptide could be related to the tau peptide associated to
lysosomes [3].
In summary, we suggest that secretion through membrane ves-
icles could be a mechanism to control (proteostasis) tau concentra-
tion, below a limited threshold level in cells.Acknowledgements
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